NCT00681343已完成4 期
Head-to-Head Comparison of Thymoglobulin vs. Campath-1H vs. Our Standard Center Treatment Protocol in Living Donor Renal Transplantation - A Study to Evaluate the Avoidance of Long-Term Nephrotoxic Calcineurin Inhibitor Therapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 38
- 试验地点
- 1
- 主要终点
- Incidence and severity of biopsy-proven acute rejection at 1 year.
研究概览
简要总结
To observe in a randomized prospective pilot study the effectiveness and toxicity of Thymoglobulin vs. Campath-1H used for induction therapy in recipients of living donor (LD) kidneys, compared with our standard treatment protocol of Zenapax® and maintenance immunosuppression
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 16 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient has been fully informed and has signed a dated IRB approval informed consent form and is willing to follow study procedures for the extent of the study (36 months). Parent or legal guardian must provide written consent for patients <18 years of age.
- •Age 16-65 years
- •Weight > 40 kg
- •Primary renal allograft: living related (non HLA identical) and unrelated donor
- •Negative standard cross-match for T-cells. All donor-recipient pairs matched for a minimum of 1 HLA DR antigen. (Standard at our center)
- •Women of childbearing potential will be required to have a negative qualitative serum pregnancy test and agree to use an adequate method of contraception for 3 months following discontinuation of Thymoglobulin or Campath-1H
- •Males and females are to be studied equivalently as they become available for transplantation using these criteria.
排除标准
- •Patient has previously received or is receiving an organ transplant other than a kidney.
- •Patient is receiving an ABO incompatible donor kidney.
- •Recipient or donor is seropositive for human immunodeficiency virus (HIV), Hepatitis C viruses, or Hepatitis B virus antigenemia.
- •Patient has a current malignancy or a history of malignancy (within the past 5 years), except non-metastatic basal or squamous cell carcinoma of the skin that has been treated successfully or carcinoma in situ of the cervix that has been treated successfully.
- •Patients with significant liver disease, defined as having during the past 28 days continuously elevated AST (SGOT) and/or ALT (SGPT) levels greater than 3 times the upper value of the normal range of this center.
- •Patient has uncontrolled concomitant infections and/or severe diarrhea, vomiting, active upper gastro-intestinal tract malabsorption or an active peptic ulcer or any other unstable medical condition that could interfere with study objectives.
- •Patient is currently participating in another clinical trial of an investigational drug in the 30 days prior to transplant.
- •Patient will be receiving any immunosuppressive agent other that those prescribed in the study.
- •Patient is unable to take medications orally or via nasogastric tube by the morning of the second day following completion of the transplant procedure (i.e. skin closure).
- •Patient is receiving or may require warfarin, fluvastatin or herbal supplements during the study.
- •Concurrent use of astemizole, pimozide, cisapride, terfenadine, or ketoconazole.
- •Patient has a known hypersensitivity to Tacrolimus, Campath-1H, Thymoglobulin, Daclizumab (Zenapax®), Sirolimus, MMF or corticosteroids.
- •Patient is pregnant or lactating.
- •Patients with a screening/baseline (or within 96 hours of transplant) total white blood cell count <4000/mm3; platelet count <100,000/mm3; fasting triglycerides >400 mg/dl (>4.6 mmol/L); fasting total cholesterol >300 mg/dl (>7.8 mmol/L); fasting HDL-cholesterol <30 mg/dl; fasting LDL-cholesterol >200mg/dl.
- •Patient is unlikely to comply with the visits scheduled in the protocol.
- •Patient has any form of substance abuse, psychiatric disorder or a condition that, in opinion of the investigator, may invalidate communication with the investigator.
- •If tacrolimus cannot be instituted for longer than 5 days postoperatively.
研究组 & 干预措施
A
Experimental
Thymoglobulin Induction
干预措施: Thymoglobulin (Drug)
B
Experimental
Campath-1H Induction
干预措施: Campath-1H (Drug)
C
Experimental
Daclizumab Induction
干预措施: Daclizumab (Drug)
结局指标
主要结局
Incidence and severity of biopsy-proven acute rejection at 1 year.
时间窗: 1 year
次要结局
- Incidence of biopsy-proven chronic allograft nephropathy.(1 and 3 years)
- Incidence of adverse reactions, for example: Infections, Malignancies, Thromboembolic events.(1 and 3 years)
- Patient and graft survival(1 and 3 years)
- Levels of lymphoid cell subsets.(1 and 3 years)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Thymoglobulin Versus Alemtuzumab Versus Daclizumab in Living Donor Renal TransplantationEnd-Stage Renal DiseaseLiving DonorsNCT01046955University of Miami38
已完成
4 期
Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Deceased Donor Renal TransplantationRenal TransplantationNCT00685061University of Miami90
已完成
3 期
Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive CrossmatchKidney Failure, ChronicNCT00275509Johns Hopkins University56
已完成
2 期
Thymoglobulin and Cyclosporine in Patients With Aplastic Anemia or Myelodysplastic SyndromeMyelodysplastic SyndromeAplastic AnemiaNCT00806598M.D. Anderson Cancer Center53
进行中（未招募）
2 期
ATG Plus PTCy vs ATG for CGVHD ProphylaxisMyelodysplasiaChronic Graft-versus-host-diseaseAcute LeukemiaNCT04202835McMaster University80